At Tel Aviv Univ. (TAU), researchers are using lipid nanoparticles to deliver RNA therapeutics to treat inflamed cells, such as those affected by inflammatory bowel disease (IBD) and Crohn’s disease. IBD is a chronic disease, which entails a lifelong dependence on medication that can have many side effects.
Most modern treatments for IBD rely on antibodies that target TNF-alpha, an inflammatory cytokine produced during acute inflammation. However, this method is not wholly effective, as its effects can wane over time.
Generally, inflammation refers to an immune response that can cause pain and discomfort. In the case of IBD, chronic inflammation can cause persistent diarrhea, abdominal pain, and even ulcers.
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.